Gary Patou
Independent DirectorDr. Gary Patou, M. D., was Chief Medical Officer at STAR Therapeutics Inc until 2026. He has extensive expertise in designing innovative clinical development pathways for novel therapies and translational science—the art of turning laboratory, clinic and community observations into interventions that improve the health of patients. He has served as Chief Medical Officer for numerous companies, including True North Therapeutics, Pacira, Chiasma and Peplin. He has led successful phase 3 clinical trials leading to the approval of five new drug applications since 2020. Prior to his tenure in biotech, he was Senior Vice President for Drug Development at GSK. He served as the Executive Partner at MPM Capital. He joined MPM in 2005 and now serves as the Head of Clinical for Chiasma Pharmaceuticals. Dr. Patou has served as a Chief Medical Officer at Star Therapeutics Incorporated. He has been Chief Medical Officer of Bioverativ USA Inc., since November 14, 2016. He served as an Advisor of MPM Capital since August 2020. Dr. Patou has served as a Member of the Board of Directors and Chief Medical Officer for BioIntervene Inc., a preclinical-stage biopharmaceutical company, since January 2019. He has served as Interim Chief Medical Officer in various MPM portfolio companies, including at Blade Therapeutics from October 2018 to December 2020. Dr. Patou has been Managing Director at MPM Capital since May 2005. Dr. Patou serves as Managing Director at MPM BioVentures IV, L. P. He had been Head of Clinical at Chiasma, Inc. since March 8, 2016 until 2020. He has been Senior Medical Advisor at Chiasma (Israel) ltd., since 2014. He served as Senior Medical Advisor at Chiasma, Inc., since August 2014 until March 8, 2016. He was a Consultant at Peplin Inc. He previously served as Chief Medical Officer at Pacira Pharmaceuticals, Inc., from March 2009 to August 21, 2015. Prior to joining MPM, Dr. Patou was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals Corporation from February 2004 to April 2005. Before GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of its pharmaceutical development projects. He has been Independent Director at Xenon Pharmaceuticals Inc., since January 2004. He served as Chairman of Scientific and Medical Advisory Board at Cerimon Pharmaceuticals, Inc. He served as Director at Oscient Pharmaceuticals Corp. Dr. Patou served a number of academic appointments at University College and Middlesex School of Medicine in London. He holds a B. Sc. M. B. B. S. and an M. D. from University College London.
公司職務
- 公司名稱Xenon Pharmaceuticals Inc.股票代碼XENE職務Independent Director共事同僚
- ICIan C. MortimerPresident, CEO & Director
- DADawn A. SvoronosIndependent Chairman
- TPThomas Patrick KellyChief Financial Officer
- ADAndrea DiFabioChief Legal Officer & Corporate Secretary
- CJChristopher John KenneyChief Medical Officer
- DSDarren S. ClineChief Commercial Officer
- SRSteven R. GannonIndependent Director
- JDJustin D. GoverIndependent Director
